Quality-adjusted survival analysis of malignant glioma patients |
| |
| Affiliation: | 1. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana;2. Indiana University Health Proton Therapy Center, Bloomington, Indiana;1. Department of Pediatric Neurology (DY) University of Health Sciences, Dr. Sami Ulus Maternity and Children''s Health and Diseases Training and Research Hospital, Ankara, Turkey;2. Child and Adolescent Psychiatry Department University of Health Sciences, Dr. Sami Ulus Maternity and Children''s Health and Diseases Training and Research Hospital, Ankara, Turkey;1. Centre for Health Economics, University of York, York, UK;2. Department of Economics and Related Studies, University of York, York, UK;1. Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands;2. Department of Research and Development, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands;3. Trimbos Institute, National Institute of Mental Health and Addiction, Utrecht, The Netherlands;4. Department of Neurology, Academic Center for Epileptology Kempenhaeghe & Maastricht UMC+, Heeze, The Netherlands;5. Department of Behavioral Sciences, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands;6. Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands;7. Faculty of Electrical Engineering, University of Technology, Eindhoven, The Netherlands;8. School of Health Professions Education, Faculty of Health, Medicine and Life Sciences, Maastricht University, The Netherlands;1. Departments of Child Neurology and Public Health, University of Turku and Turku University Hospital, Turku, Finland;2. Epilepsy Research Group, Berlin, Germany |
| |
| Abstract: | The goal of therapeutic intervention in oncology patients is to prolong survival without compromising its quality. Definition and measurement of quality are quite difficult. This article discusses the statistical techniques for quantifying quality survival that have been used in brain tumor patients. These techniques assume either that all patients have equivalent baseline quality of life when both disease-related symptoms and toxicities are absent, or that the length of time with a predetermined level of impairment is equivalent to death. These models do not fit the heterogeneous symptoms experienced by patients with malignant brain tumors. We propose a model that incorporates the baseline states with transitions to different levels of severity that indicate improvement and/or declines in physical and cognitive functioning of brain tumor patients. The length of time spent in each state is observed and weighted by using predetermined utilities. The weighted time spent in each state is aggregated over all states into a quality-time of survival metric (QTIME). This QTIME model was applied to a previously published, randomized clinical trial of different radiation doses in malignant brain tumor patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
